Jeannette Bankes (GEHC) receives stock options and RSUs from GE HealthCare

Rhea-AI Filing Summary

Bankes Jeannette reported acquisition or exercise transactions in this Form 4 filing.

GE HealthCare Technologies Inc. reported that Jeannette Bankes, CEO of Patient Care Solutions, received new equity awards. On March 2, 2026, she was granted an employee stock option for 18,038 shares of common stock and 6,861 restricted stock units, both at no cash cost.

The restricted stock units each represent one share of GE HealthCare common stock and are scheduled to vest 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. The stock option becomes exercisable on the same 33/33/34 schedule. Following these awards, she directly holds 43,892 shares of common stock and 18,038 options.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Bankes Jeannette

Role CEO, Patient Care Solutions

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	18,038	$0.00	--
Grant/Award	Common Stock, par value $0.01 per share	6,861	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 18,038 shares (Direct); Common Stock, par value $0.01 per share — 43,892 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare Technologies Inc. ("GE HealthCare") common stock. Award of restricted stock units with respect to GE HealthCare common stock, of which 33% will vest on September 2, 2027, 33% will vest on September 2, 2028, and 34% will vest on September 2, 2029. Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 2, 2027, 33% will become exercisable on September 2, 2028, and 34% will become exercisable on September 2, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bankes Jeannette

(Last) (First) (Middle)

500 WEST MONROE STREET

(Street)

CHICAGO IL 60661

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GE HealthCare Technologies Inc. [ GEHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, Patient Care Solutions

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.01 per share	03/02/2026		A		6,861(1)(2)	A	$0	43,892	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$80.16	03/02/2026		A		18,038		(3)	03/02/2036	Common Stock, par value $0.01 per share	18,038	$0(3)	18,038	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive, at settlement, one share of GE HealthCare Technologies Inc. ("GE HealthCare") common stock.

2. Award of restricted stock units with respect to GE HealthCare common stock, of which 33% will vest on September 2, 2027, 33% will vest on September 2, 2028, and 34% will vest on September 2, 2029.

3. Award of an employee stock option with respect to GE HealthCare common stock, of which 33% will become exercisable on September 2, 2027, 33% will become exercisable on September 2, 2028, and 34% will become exercisable on September 2, 2029.

Remarks:

	/s/ Frank R. Jimenez, General Counsel and Corporate Secretary, as attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jeannette Bankes receive in this GEHC Form 4 filing?

Jeannette Bankes received new equity awards from GE HealthCare. She was granted 18,038 employee stock options and 6,861 restricted stock units, each tied to common shares, as part of her compensation as CEO of Patient Care Solutions on March 2, 2026.

How many GE HealthCare restricted stock units were granted to Jeannette Bankes?

Jeannette Bankes was granted 6,861 restricted stock units. Each restricted stock unit represents the right to receive one share of GE HealthCare common stock upon settlement, providing additional equity-based compensation linked directly to the company’s share performance over time.

What is the vesting schedule for Jeannette Bankes’ GEHC restricted stock units?

The restricted stock units vest in three tranches over time. Thirty-three percent vest on September 2, 2027, another 33% on September 2, 2028, and the remaining 34% on September 2, 2029, aligning her incentives with longer-term company performance.

When do Jeannette Bankes’ GE HealthCare stock options become exercisable?

The employee stock options become exercisable in stages. Thirty-three percent of the 18,038 options become exercisable on September 2, 2027, another 33% on September 2, 2028, and the final 34% on September 2, 2029, mirroring the restricted stock unit schedule.

How many GEHC shares does Jeannette Bankes own after these awards?

After these awards, Jeannette Bankes directly holds 43,892 shares of GE HealthCare common stock. She also holds 18,038 employee stock options, giving her additional potential future ownership if and when those options are exercised under their terms.

Are Jeannette Bankes’ GE HealthCare equity awards open-market purchases or grants?

These are compensation grants, not open-market purchases. The Form 4 uses transaction code “A” and describes them as grants or awards, with a reported transaction price per share of $0.0000, indicating they were awarded as part of her executive compensation package.